Avalo Therapeutics AVTX Insider Ownership

NASDAQ AVTX

$12.48 +0.12 (+0.93%)

As of: Oct 21, 2026 · 1:50 PM EDT

Insider Holdings by Owner

388.93K Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

0.720%

▼-0.0067% pp QoQ

Shares Held by Insiders

381.11K

filed for Sep 2026

▼-0.92% QoQ

Shares Outstanding

52.90Mn

52,900,692 shares

Direct Holdings

380.11K

Indirect: 1.00K

Net Shares Traded (QoQ)

-3.53K

net selling in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Over the past 12 months, Avalo Therapeutics insiders sold $8.5 million of stock on the open market (437.55K shares) and made no open-market purchases.

Avalo Therapeutics' open-market sales in the past 12 months came from 6 insiders; no insider bought.
Christopher Ryan Sullivan (Chief Financial Officer) led open-market sales of Avalo Therapeutics stock over the past 12 months with $3.72 million (193.78K shares), most recently on September 16, 2026.
Apart from open-market trades, AVTX insiders received 242.1K shares in stock awards, acquired 487.05K shares through option exercises and conversions and gave up 35.84K shares to cover taxes or exercise prices in the past 12 months.
Per Business Quant data, Avalo Therapeutics insiders hold 381.11K shares in total based on their latest Form 4 filings, or 0.72% of the 52.9Mn shares outstanding; that total is down 0.92% from 384.63K shares at the end of Q2 2026 and up 353.36% from 84.06K shares at the end of Q3 2025.
Of the 381.11K shares held by Avalo Therapeutics insiders, 380.11K shares (99.74%) are held directly and 1K shares (0.26%) indirectly, through trusts, partnerships, family members and other entities.
The insider holdings in Avalo Therapeutics belong to 11 insiders who have reported on Form 4 within the past two years.
Avalo Therapeutics' three biggest insider holders are Garry Arthur Neil (Chief Executive Officer, 190.31K shares), Mittie Doyle (Chief Medical Officer, 51.78K shares) and Christopher Ryan Sullivan (Chief Financial Officer, 39.9K shares), based on their latest Form 4 filings.
The holding of Garry Arthur Neil makes up 49.94% of all shares held by Avalo Therapeutics insiders.
In the past year, 15 insiders of Avalo Therapeutics submitted 66 Form 4 filings reporting trades, awards or other transactions.
The insider data for AVTX reflects Form 4 filings through October 2, 2026.

Form 4 Holdings

Insiders Holding AVTX

Insiders 13

Shares held 388.93K

Of outstanding 0.735%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Garry Arthur Neil	Chief Executive Officer	190,314	0	190,314	48.9%	26 May, 2026
2	Mittie Doyle	Chief Medical Officer	51,776	0	51,776	13.3%	01 Sep, 2026
3	Christopher Ryan Sullivan	Chief Financial Officer	39,900	0	39,900	10.3%	18 Sep, 2026
4	Jennifer Riley	Chief Strategy Officer	37,041	0	37,041	9.5%	12 Aug, 2026
5	Paul Varki	Chief Legal Officer	32,576	0	32,576	8.4%	12 Jun, 2026
6	Gilla Kaplan	Director	6,333	0	6,333	1.6%	31 Mar, 2026
7	Aaron Kantoff	Director	6,333	0	6,333	1.6%	31 Mar, 2026
8	Samantha Truex	Director	6,333	0	6,333	1.6%	31 Mar, 2026
9	Capital Management Ltd. Caissa	TenPercentOwner	0	5,777	5,777	1.5%	30 May, 2023
10	June Sherie Almenoff	Director	3,167	0	3,167	0.8%	01 Apr, 2025
11	Jonathan Goldman	Director	3,166	0	3,166	0.8%	31 Mar, 2026
12	Mitchell Chan	Director	3,166	0	3,166	0.8%	07 May, 2026
13	Capital, Llc Armistice	TenPercentOwner	0	3,050	3,050	0.8%	28 Jun, 2023

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

854 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
30 Sep, 2026	Ron M Philip	Director	Acquired A	1,109	$12.29	$13.63K	1,109	Direct
30 Sep, 2026	Rita Jain	Director	Acquired A	1,322	$12.29	$16.25K	1,322	Direct
30 Sep, 2026	Kevin Robert Lind	Director	Acquired A	1,352	$12.29	$16.62K	1,352	Direct
16 Sep, 2026	Christopher Ryan Sullivan	Chief Financial Officer	Acquired M	12,394	$9.88	$122.45K	52,294	Direct
16 Sep, 2026	Christopher Ryan Sullivan	Chief Financial Officer	Disposed S	12,394	$16.33	$202.44K	39,900	Direct
16 Sep, 2026	Christopher Ryan Sullivan	Chief Financial Officer	Disposed M	12,394	$0.00	$0	83,848	Direct
10 Sep, 2026	Christopher Ryan Sullivan	Chief Financial Officer	Acquired M	10,185	$8.04	$81.89K	50,085	Direct
10 Sep, 2026	Christopher Ryan Sullivan	Chief Financial Officer	Disposed S	10,185	$17.62	$179.46K	39,900	Direct
10 Sep, 2026	Christopher Ryan Sullivan	Chief Financial Officer	Disposed M	10,185	$0.00	$0	105,815	Direct
28 Aug, 2026	Mittie Doyle	Chief Medical Officer	Acquired M	679	$8.04	$5.46K	52,455	Direct
28 Aug, 2026	Mittie Doyle	Chief Medical Officer	Disposed S	679	$20.00	$13.58K	51,776	Direct
28 Aug, 2026	Mittie Doyle	Chief Medical Officer	Disposed M	679	$0.00	$0	113,734	Direct
17 Aug, 2026	Christopher Ryan Sullivan	Chief Financial Officer	Acquired M	37,945	$9.88	$374.90K	78,718	Direct
17 Aug, 2026	Mittie Doyle	Chief Medical Officer	Acquired M	1,000	$12.65	$12.65K	52,776	Direct
17 Aug, 2026	Christopher Ryan Sullivan	Chief Financial Officer	Acquired M	2,876	$9.88	$28.41K	81,594	Direct
17 Aug, 2026	Mittie Doyle	Chief Medical Officer	Disposed S	1,000	$20.00	$20.00K	51,776	Direct
17 Aug, 2026	Mittie Doyle	Chief Medical Officer	Disposed M	1,000	$0.00	$0	123,750	Direct
17 Aug, 2026	Christopher Ryan Sullivan	Chief Financial Officer	Disposed S	37,945	$19.85	$753.33K	43,649	Direct
17 Aug, 2026	Christopher Ryan Sullivan	Chief Financial Officer	Disposed S	3,749	$19.94	$74.76K	39,900	Direct
18 Aug, 2026	Christopher Ryan Sullivan	Chief Financial Officer	Acquired M	31,031	$9.88	$306.59K	70,931	Direct

Showing 1 to 20 of 854 transactions